Replimune Group, Inc. (REPL) Social Stream
Replimune Group Inc (REPL) Price Targets From Analysts
Use the tables below to see what analysts covering Replimune Group Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
REPL's average price target has moved down $2.17 over the prior 41 weeks.
Over the past 44 weeks, REPL's average upside potential has been 80.44%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
REPL Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 26 weeks, REPL's average broker recommendation rating improved by 0.6.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for REPL as an investment opportunity.
- In terms of how Replimune Group Inc fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 542.28% of that group.
- Replimune Group Inc's variance in analysts' estimates is lower than -42.05% of Pharmaceutical Products stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Replimune Group Inc's average analyst price target is higher than 434.3% of them.
- Replimune Group Inc's number of analysts covering the stock is higher than 377.49% of Pharmaceutical Products stocks.
Is REPL a Buy, Hold or Sell? See the POWR Ratings now!